Edward Tenthof

Edward Tenthoff is a Managing Director and Senior Research Analyst at Piper Sandler, specializing in drug discovery and biotechnology, with coverage spanning more than 70 healthcare and biotech companies such as Moderna, Alnylam Pharmaceuticals, and Arrowhead Pharmaceuticals. With over 1,400 published stock ratings and a consistent focus on the healthcare sector, his track record includes a price target met ratio of about 45%, though recent reports indicate a success rate near 28% and an average return per recommendation of -17.2%, with standout returns such as a 366% gain on Poseida Therapeutics. Tenthoff began his career as a medical technology analyst at Lehman Brothers, then covered genomics at Robertson Stephens & Company, before joining Piper Sandler in 2003. He holds a bachelor's degree from the University of Pennsylvania, has earned multiple sector awards including top stock picker accolades from the Wall Street Journal and Starmine, and is a registered securities professional with FINRA credentials.